Equities Analysts Set Expectations for Tenax Therapeutics, Inc.s Q3 2024 Earnings
| TENX Stock | USD 5.94 0.29 5.13% |
Slightly above 54% of Tenax Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Tenax Therapeutics suggests that some traders are interested. Tenax Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tenax Therapeutics' earnings reports, geopolitical events, and overall market trends.
Tenax |
Tenax Therapeutics, Inc. Analysts at William Blair issued their Q3 2024 EPS estimates for Tenax Therapeutics in a research report issued to clients and investors on Monday, September 30th. William Blair analyst M. Phipps anticipates that the specialty pharmaceutical company will post earnings per share of for the quarter.
Read at thelincolnianonline.com
 |
Tenax Therapeutics Fundamental Analysis
We analyze Tenax Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tenax Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tenax Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Tenax Therapeutics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Tenax Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tenax Therapeutics stock to make a market-neutral strategy. Peer analysis of Tenax Therapeutics could also be used in its relative valuation, which is a method of valuing Tenax Therapeutics by comparing valuation metrics with similar companies.
Peers
Tenax Therapeutics Related Equities
| UNCY | Unicycive Therapeutics | 9.59 | ||||
| QNRX | Quoin Pharmaceuticals | 5.48 | ||||
| ALLR | Allarity Therapeutics | 2.94 | ||||
| ADTX | Aditxt | 2.86 | ||||
| CYTO | Altamira Therapeutics | 2.17 | ||||
| ZVSA | ZyVersa Therapeutics | 1.75 | ||||
| NRBO | Neurobo Pharmaceuticals | 2.59 | ||||
| SONN | Sonnet Biotherapeutics | 3.54 | ||||
| ENSC | Ensysce Biosciences | 4.99 | ||||
| WINT | Windtree Therapeutics | 5.41 | ||||
| VRAX | Virax Biolabs | 6.08 | ||||
| DRMA | Dermata Therapeutics | 6.57 | ||||
| REVB | Revelation Biosciences | 6.67 |
Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.